The 2012 Meeting Season

November 2011 – June 2012

Malnutrition, Gut–Microbial Interactions and Mucosal Immunity to Vaccines
November 7–11, 2011 • Le Meridien New Delhi • New Delhi • India

Chemoskines and Leukocyte Trafficking in Homeostasis and Inflammation
January 8–13, 2012 • Beaver Run Resort • Breckenridge, Colorado • USA

Nucleic Acid Therapeutics: From Base Pairs to Bedsides
January 10–15, 2012 • Eldorado Hotel & Spa • Santa Fe, New Mexico • USA

Drug Discovery for Protozoan Parasites
joint with Fungal Pathogens: From Basic Biology to Drug Discovery
January 15–20, 2012 • Santa Fe Community Convention Center • Santa Fe, New Mexico • USA

Angiogenesis: Advances in Basic Science and Therapeutic Applications
January 16–21, 2012 • Snowbird Resort • Snowbird, Utah • USA

Epigenomics joint with Chromatin Dynamics
January 17–22, 2012 • Keystone Resort • Keystone, Colorado • USA

Rheumatoid Arthritis: Molecular and Clinical Insights
January 19–24, 2012 • Eldorado Hotel & Spa • Santa Fe, New Mexico • USA

Membranes in Motion: From Molecules to Disease
January 22–27, 2012 • Granlibakken Resort • Tahoe City, California • USA

Cardiovascular Development and Regeneration
January 22–27, 2012 • Sagebrush Inn and Conference Center • Taos, New Mexico • USA

High-Throughput Structural Biology
joint with Integrative Structural Biology: From Atoms to Cells
January 22–27, 2012 • Keystone Resort • Keystone, Colorado • USA

Genetic and Molecular Basis of Obesity and Body Weight Regulation
joint with Emerging Molecular Mechanisms for the Pathogenesis of Diabetes
January 29–February 3, 2012 • Santa Fe Community Convention Center • Santa Fe, New Mexico • USA

The Biology of Cytokines
joint with Th17 Cells in Health and Disease
February 5–10, 2012 • Keystone Resort • Keystone, Colorado • USA

Gene Silencing by Small RNAs
February 7–12, 2012 • Fairmont Hotel Vancouver • Vancouver, British Columbia • Canada

Sirtuins in Metabolism, Aging and Disease
February 12–16, 2012 • Granlibakken Resort • Tahoe City, California • USA

Chemical Biology and Novel Tools in Pharmacology
February 12–16, 2012 • Hilton Santa Fe/Historic Plaza • Santa Fe, New Mexico • USA

Cancer and Metabolism
joint with Advances in Hypoxic Signaling: From Bench to Bedside
February 12–17, 2012 • Fairmont Banff Springs • Banff, Alberta • Canada

G Protein–Coupled Receptors: Molecular Mechanisms and Novel Functional Insights
February 17–22, 2012 • Fairmont Banff Springs • Banff, Alberta • Canada

Complex Traits: Genomics and Computational Approaches
February 20–25, 2012 • Beaver Run Resort • Breckenridge, Colorado • USA

Apoe, Alzheimer’s and Lipoprotein Biology
joint with Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies
February 26–March 2, 2012 • Keystone Resort • Keystone, Colorado • USA

Protein–RNA Interactions in Biology and Disease
March 4–9, 2012 • Hilton Santa Fe/Historic Plaza • Santa Fe, New Mexico • USA

Innate Immunity: Sensing the Microbes and Damage Signals
joint with The Microbiome
March 4–9, 2012 • Keystone Resort • Keystone, Colorado • USA

Nuclear Events in Plant Gene Expression and Signaling
March 6–11, 2012 • Sagebrush Inn and Conference Center • Taos, New Mexico • USA

The Life of a Stem Cell: From Birth to Death
March 11–16, 2012 • Resort at Squaw Creek • Olympic Valley, California • USA

Regulation of Lymphocyte Signaling
March 11–16, 2012 • Keystone Resort • Keystone, Colorado • USA

Complications of Diabetes: Mechanisms of Injury and Failure of Repair
March 11–16, 2012 • Boston Park Plaza & Towers • Boston, Massachusetts • USA

Mutations, Malignancy and Memory – Antibodies and Immunity
March 18–22, 2012 • Boston Park Plaza & Towers • Boston, Massachusetts • USA

NF–kB Signaling and Biology: From Bench to Bedside
joint with Ubiquitin Signaling
March 18–23, 2012 • Whistler Conference Centre • Whistler, British Columbia • Canada

Drug Design: Meeting the Challenges of Drug Discovery
March 19–23, 2012 • Granlibakken Resort • Tahoe City, California • USA

Mitochondrial Dynamics and Function
joint with Cell Death Pathways: Beyond Apoptosis
March 19–24, 2012 • Fairmont Banff Springs • Banff, Alberta • Canada

HIV Vaccines joint with Viral Immunity and Host Gene Influence
March 21–26, 2012 • Keystone Resort • Keystone, Colorado • USA

Molecular Basis of Vascular Inflammation and Atherosclerosis
March 25–30, 2012 • Big Sky Resort • Big Sky, Montana • USA

Advances in Islet Biology
March 25–30, 2012 • Portola Hotel & Spa • Monterey, California • USA

Cell Biology of Virus Entry, Replication and Pathogenesis
joint with Frontiers in HIV Pathogenesis, Therapy and Eradication
March 26–31, 2012 • Whistler Conference Centre • Whistler, British Columbia • Canada

Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics
March 30–April 4, 2012 • Big Sky Resort • Big Sky, Montana • USA

Non–Coding RNAs joint with Eukaryotic Transcription
March 31–April 5, 2012 • Snowbird Resort • Snowbird, Utah • USA

Synapses and Circuits: From Formation to Disease
April 1–6, 2012 • Sheraton Steamboat Resort • Steamboat Springs, Colorado • USA

Regenerative Tissue Engineering and Transplantation
joint with Mechanisms of Whole Organ Regeneration
April 1–6, 2012 • Beaver Run Resort • Breckenridge, Colorado • USA

Nuclear Receptor Matrix: Reloaded
April 15–20, 2012 • Fairmont Chateau Whistler • Whistler, British Columbia • Canada

Proteomics, Interactomes
May 7–12, 2012 • Clarion Hotel Sign • Stockholm • Sweden

Drug Resistance and Persistence in Tuberculosis
May 13–18, 2012 • Speke Resort & Conference Centre • Kampala • Uganda

The Role of Inflammation during Carcinogenesis
May 20–25, 2012 • Royal Dublin Society • Dublin • Ireland
From the Chair of the Board

In 2012, Keystone Symposia celebrated the 40th anniversary of its very first meeting, which took place March 12-17, 1972 in Squaw Valley, California on membrane biology. At that time, the organization was simply known as the UCLA Symposium, and only one meeting per year was envisioned. It wasn’t until 1980 that the organization expanded to holding three meetings per year, and growth has continued every year since. Keystone Symposia is now a completely independent nonprofit organization and holds 50-60 conferences annually throughout the world across a broad array of the life sciences, focusing on biomedical research areas that hold real promise for positive impact on the most pressing health issues of our time.

The organization’s growth would not be possible without the loyal and ongoing support of the corporations, foundations, government institutes and individuals listed later in this Annual Report. Via funding of scholarships and travel awards, their support also enables young investigators and those from developing countries to attend conferences that would be otherwise beyond reach. The entire Board of Directors joins the staff in thanking these dedicated supporters and commending them for the commitment they have demonstrated to our mission.

What will the next 40 years bring? We have every faith that in spite of the rapidly changing nature of science communication and collaboration, the value of face-to-face conferences will never wane. At the same time, the organization is actively exploring how new virtual technologies might supplement the conferences and broaden their reach so that even more participants might benefit. The organization is very well positioned to have an ever-growing impact on life science discovery.

Sincerely,

Juleen R. Zierath
Chair, Board of Directors, Keystone Symposia and Professor, Karolinska Institutet

From the Chief Executive Officer

This letter gives me the opportunity to praise all the people who contribute to the quality of Keystone Symposia meetings. Credit belongs to the Scientific Advisory Board (SAB), which recommends topics and scientific organizers; the Scientific Organizers, who design the programs and select speakers, and each of the Keystone Symposia staff, who help implement the conferences and make them hospitable. In addition, each year, even before the SAB gets the process started, many scientists contribute ideas about potential meeting topics online and via responses to post-meeting surveys.

In 2012, we received a new grant from the Bill & Melinda Gates Foundation that will support travel awards for scientists coming to our meetings from developing countries for fiscal years 2013, 2014 and 2015. Overall support for the conferences from corporate, government, private foundation and individual contributors was the best ever, which comprised about 38% of our operating budget. Exit surveys indicate that attendees rated highly the opportunities for professional development at our conferences, and also gave high ratings for impact on their research, regardless of career stage, affiliation or meeting role.

Each year we try some new things: novel topics or pairings of joint meetings, global venues, city venues, programming of ancillary workshops on related themes, activities to enhance the participation and value for early-career scientists. For example, in 2012 we held our first meetings in India (New Delhi) and Sweden (Stockholm), and another meeting in Kampala, Uganda, a popular venue that we have used before. We held our first meeting on Traumatic Brain Injury, a topic that is receiving increasing awareness of its importance in medicine especially as it relates to sports and battlefield injuries. The feedback we receive from attendees on these experiments is extremely helpful for our planning of future symposia.

Thank you to all who contribute to Keystone Symposia. We would not be able to accomplish our mission without your support.

James W. Aiken, Ph.D.
President and Chief Executive Officer, Keystone Symposia
Breakdown of the Year

The charts below are intended to provide a snapshot of Keystone Symposia’s 2012 finances and activities. Please visit keystonesymposia.org/AboutUs/AnnualReport.cfm to view the full audited statement of financial condition and statement of activities for the fiscal year July 1, 2011 – June 30, 2012.

2012 EXPENSE BREAKDOWN

- Educational Programs (74.25%)
- Management & General (12.78%)
- Scholarships, Travel Awards & Diversity Initiatives (9.30%)
- Fundraising & Development (3.67%)

A full 83.55% of Keystone Symposia’s expenditures go toward educational programs including meeting programs, scholarships, travel awards and diversity initiatives.

2012 REVENUE BREAKDOWN

- Registration Fees/ Earned Income (55.60%)
- Corporate & Foundation Gifts (31.98%)
- Government Grants (5.64%)
- Individual Gifts (.30%)
- Investment Income/ Miscellaneous Income (6.48%)

4
TOTAL MEETING ATTENDANCE & ABSTRACT SUBMISSIONS*  

<table>
<thead>
<tr>
<th>Year</th>
<th>Attendees &amp; Speakers</th>
<th>Abstract Submissions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>13,956</td>
<td>9,299</td>
</tr>
<tr>
<td>2004</td>
<td>7,340</td>
<td>7,117</td>
</tr>
<tr>
<td>2005</td>
<td>13,509</td>
<td>6,817</td>
</tr>
<tr>
<td>2006</td>
<td>6,587</td>
<td>6,546</td>
</tr>
<tr>
<td>2007</td>
<td>6,857</td>
<td>6,459</td>
</tr>
<tr>
<td>2008</td>
<td>7,340</td>
<td>6,573</td>
</tr>
<tr>
<td>2009</td>
<td>7,340</td>
<td>7,381</td>
</tr>
<tr>
<td>2010</td>
<td>6,597</td>
<td>6,603</td>
</tr>
</tbody>
</table>

*abstract count does not include speaker abstracts

AVERAGE ATTENDANCE & ABSTRACTS* PER MEETING  

<table>
<thead>
<tr>
<th>Year</th>
<th>Average Attendance</th>
<th>Average Number of Abstracts*</th>
<th>Number of Meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>252</td>
<td>41</td>
<td>123</td>
</tr>
<tr>
<td>2004</td>
<td>244</td>
<td>46</td>
<td>117</td>
</tr>
<tr>
<td>2005</td>
<td>262</td>
<td>44</td>
<td>130</td>
</tr>
<tr>
<td>2006</td>
<td>241</td>
<td>54</td>
<td>110</td>
</tr>
<tr>
<td>2007</td>
<td>270</td>
<td>50</td>
<td>132</td>
</tr>
<tr>
<td>2008</td>
<td>242</td>
<td>56</td>
<td>122</td>
</tr>
<tr>
<td>2009</td>
<td>241</td>
<td>58</td>
<td>127</td>
</tr>
<tr>
<td>2010</td>
<td>237</td>
<td>52</td>
<td>126</td>
</tr>
<tr>
<td>2011</td>
<td>250</td>
<td>55</td>
<td>134</td>
</tr>
<tr>
<td>2012</td>
<td>225</td>
<td>55</td>
<td>120</td>
</tr>
</tbody>
</table>

*abstract count does not include speaker abstracts

SCHOLARSHIPS & TRAVEL AWARDS  

<table>
<thead>
<tr>
<th>Year</th>
<th>Scholarships</th>
<th>Underrepresented Trainee Scholarships</th>
<th>Global Health Travel Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>459</td>
<td>546</td>
<td>619</td>
</tr>
<tr>
<td>2004</td>
<td>619</td>
<td>546</td>
<td>619</td>
</tr>
<tr>
<td>2005</td>
<td>619</td>
<td>546</td>
<td>619</td>
</tr>
<tr>
<td>2006</td>
<td>619</td>
<td>546</td>
<td>619</td>
</tr>
<tr>
<td>2007</td>
<td>619</td>
<td>546</td>
<td>619</td>
</tr>
<tr>
<td>2008</td>
<td>711</td>
<td>681</td>
<td>619</td>
</tr>
<tr>
<td>2009</td>
<td>903</td>
<td>829</td>
<td>711</td>
</tr>
<tr>
<td>2010</td>
<td>903</td>
<td>829</td>
<td>711</td>
</tr>
<tr>
<td>2011*</td>
<td>882*</td>
<td>882*</td>
<td>882*</td>
</tr>
<tr>
<td>2012*</td>
<td>835*</td>
<td>835*</td>
<td>835*</td>
</tr>
</tbody>
</table>

*Scholarship amount was increased from $1,000 to $1,200 in 2011, which slightly reduced the total number awarded.
## Participation of the Next Generation of Investigators (Percent of Total & Absolute Numbers)

<table>
<thead>
<tr>
<th>Year</th>
<th>Assistant Professor &amp; Young Investigator Speakers &amp; Organizers</th>
<th>Total Assistant Professor &amp; Young Investigator Attendees</th>
<th>Total Student &amp; Postdoctoral Fellow Attendees</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>5,368 (40%)</td>
<td>941 (7%)</td>
<td>64 (4%)</td>
</tr>
<tr>
<td>2009</td>
<td>5,415 (39%)</td>
<td>1,143 (8%)</td>
<td>109 (7%)</td>
</tr>
<tr>
<td>2010</td>
<td>4,930 (40%)</td>
<td>1,104 (9%)</td>
<td>92 (7%)</td>
</tr>
<tr>
<td>2011</td>
<td>5,564 (41%)</td>
<td>1,403 (10%)</td>
<td>130 (9%)</td>
</tr>
<tr>
<td>2012</td>
<td>4,679 (38%)</td>
<td>1,222 (10%)</td>
<td>160 (11%)</td>
</tr>
</tbody>
</table>

## Meeting “Excellent” Ratings as a Percent of All Ratings (Based on Attendee Surveys)

- Overall Scientific Content Quality
- Scientific Value Compared to Other Meetings
- Quality of Plenary Speakers
- Poster/Abstract Quality

## Value Participants Gained from the 2012 Meetings (Based on Attendee Surveys)

- Strongly Agree
- Somewhat Agree
- Neutral
- Somewhat Disagree
- Strongly Disagree

### Participation of the Next Generation of Investigators (Percent of Total & Absolute Numbers)

<table>
<thead>
<tr>
<th>Year</th>
<th>Assistant Professor &amp; Young Investigator Speakers &amp; Organizers</th>
<th>Total Assistant Professor &amp; Young Investigator Attendees</th>
<th>Total Student &amp; Postdoctoral Fellow Attendees</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>5,368 (40%)</td>
<td>941 (7%)</td>
<td>64 (4%)</td>
</tr>
<tr>
<td>2009</td>
<td>5,415 (39%)</td>
<td>1,143 (8%)</td>
<td>109 (7%)</td>
</tr>
<tr>
<td>2010</td>
<td>4,930 (40%)</td>
<td>1,104 (9%)</td>
<td>92 (7%)</td>
</tr>
<tr>
<td>2011</td>
<td>5,564 (41%)</td>
<td>1,403 (10%)</td>
<td>130 (9%)</td>
</tr>
<tr>
<td>2012</td>
<td>4,679 (38%)</td>
<td>1,222 (10%)</td>
<td>160 (11%)</td>
</tr>
</tbody>
</table>

### Made a Useful Contact

<table>
<thead>
<tr>
<th>Year</th>
<th>(N=4,035)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>45%</td>
</tr>
<tr>
<td>2008</td>
<td>21%</td>
</tr>
<tr>
<td>2009</td>
<td>30%</td>
</tr>
<tr>
<td>2010</td>
<td>28%</td>
</tr>
<tr>
<td>2011</td>
<td>25%</td>
</tr>
<tr>
<td>2012</td>
<td>23%</td>
</tr>
</tbody>
</table>

### Saved Research Time/Money or Accelerated Research Objectives

<table>
<thead>
<tr>
<th>Year</th>
<th>(N=4,035)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>45%</td>
</tr>
<tr>
<td>2008</td>
<td>21%</td>
</tr>
<tr>
<td>2009</td>
<td>30%</td>
</tr>
<tr>
<td>2010</td>
<td>28%</td>
</tr>
<tr>
<td>2011</td>
<td>25%</td>
</tr>
<tr>
<td>2012</td>
<td>23%</td>
</tr>
</tbody>
</table>

### Meeting Facilitated Junior-Senior Interactions

<table>
<thead>
<tr>
<th>Year</th>
<th>(N=4,035)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>56%</td>
</tr>
<tr>
<td>2008</td>
<td>21%</td>
</tr>
<tr>
<td>2009</td>
<td>30%</td>
</tr>
<tr>
<td>2010</td>
<td>28%</td>
</tr>
<tr>
<td>2011</td>
<td>25%</td>
</tr>
<tr>
<td>2012</td>
<td>23%</td>
</tr>
</tbody>
</table>
Keystone Symposia is fortunate to receive substantial ongoing support from the pharmaceutical and biotechnology industries, charitable foundations and individuals. We are also honored to be the recipient of numerous grants from the US National Institutes of Health and other government agencies around the world. These gifts and grants are used to provide scholarships for graduate students and postdoctoral fellows, travel awards for scientists from developing nations and subsidies for the travel and lodging costs of scientific speakers from academic and other nonprofit laboratories and institutions.

For the 2012 meeting season and fiscal year, we received a total of $4.34 million from government, corporate, foundation and individual sources, as shown in the chart below. This funding is crucial in supporting Keystone Symposia’s mission to serve as a catalyst for the advancement of biomedical and life sciences and to accelerate applications that benefit humankind.

Keystone Symposia gratefully acknowledges donors who gave in the 2012 fiscal year. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction and collaboration among participants. To make a gift, please contact the Development office by telephone at 970.262.1474 or by e-mail at chrisatwood@keystonesymposia.org. “Future of Science Fund” individual donations can also be made over the Internet at www.keystonesymposia.org/ScienceFund. And please visit our new website, www.ksgift.org, for more information on planned giving opportunities and becoming a member of The Keystone Society. This site also provides the opportunity to honor a mentor or loved one via named funds.

Christopher Atwood, D.Min.
Director of Development, Keystone Symposia
Donor Support

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2011 and ending June 30, 2012.

**CHAMPIONS**
Top-tier donors making an ongoing, annual commitment of $100,000+. Their public championing of Keystone Symposia’s cause provides inspirational leadership commitment to our shared scientific mission of catalyzing collaborations, accelerating discoveries, and preparing and positioning the next generation of leading life scientists.

Bill & Melinda Gates Foundation
Merck & Co., Inc.
Novartis Institutes for BioMedical Research
Science for Life Laboratory – Stockholm
Knut and Alice Wallenberg Foundation

**SUSTAINING BENEFACTORS**
Donors making a three-year commitment of at least $50,000 per year. Their generous support is crucial to sustain Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Bayer USA Foundation
Takeda Pharmaceutical Company Limited

**BENEFACTORS**
Donors of $50,000 or above. We are very grateful for their extraordinary commitment to our mission to connect the scientific community and accelerate discoveries that benefit society. Special thanks to those organizations that provide consistent, annual Benefactor-level support.

American College of Rheumatology Research and Education Foundation
Educational donation provided by Amgen
Genentech, Inc.
Novo Nordisk A/S
Pfizer Inc.
Science Foundation Ireland
Stanford University via a California Institute for Regenerative Medicine (CIRM) Conference Grant

**SUSTAINING SPONSORS**
Donors making a three-year commitment of $25,000 to $49,999 per year. Their generous support is crucial to Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Abbott Laboratories
Astellas Pharma Inc.
Biogen Idec
Boehringer Ingelheim Pharmaceuticals, Inc.
Celgene Corporation
Gilead Sciences, Inc.
Hoffmann-La Roche, Inc.
Infinity Pharmaceuticals
MedImmune
Onyx Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
Sangamo BioSciences, Inc.
Vertex Pharmaceuticals Incorporated

**SPONSORS**
Donors contributing $25,000 to $49,999. These generous gifts allow us to convene meetings in a wide variety of important areas. Special thanks to those organizations that provide consistent, annual Sponsor-level support.

AstraZeneca Pharmaceuticals, L.P.
Bristol-Myers Squibb Company
GlaxoSmithKline
GlaxoSmithKline UK
Isis Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Educational grant from Lilly USA, LLC
Monsanto Company
Sanofi US
The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2011 and ending June 30, 2012.

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

**DIRECTORS’ FUND CHAMPIONS & BENEFACTORS**

The following donors with unrestricted gifts of $50,000 or more enabled Keystone Symposia’s President/CEO and Directors to schedule meetings in a variety of important areas, many of which are in the early stages of research.

Educational donation provided by Amgen
Bayer USA Foundation
Genentech, Inc.
Merck & Co., Inc.
Novartis Institutes for BioMedical Research
Novo Nordisk A/S
Pfizer Inc.
Takeda Pharmaceutical Company Limited

**DIRECTORS’ FUND SPONSORS**

The following donors with unrestricted gifts from $25,000 to $49,999 also provided invaluable support to the Directors’ Fund.

Abbott Laboratories
Astellas Pharma Inc.
Biogen Idec
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Gilead Sciences, Inc.
GlaxoSmithKline
GlaxoSmithKline UK
Hoffmann-La Roche, Inc.
Infinity Pharmaceuticals
Isis Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Educational grant from Lilly USA, LLC
MedImmune
Monsanto Company
Onyx Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
Sangamo BioSciences, Inc.
Sanofi US
Vertex Pharmaceuticals Incorporated

**DIVERSITY PROGRAM SUPPORT**

Keystone Symposia is grateful to the following 2012 supporters of its Diversity in Life Science Programs.

Biogen Idec
Novartis Institutes for BioMedical Research

National Institute of General Medical Sciences (NIGMS), NIH, Minority Access to Research Careers (MARC)

**PARTNERS, PATRONS, DONORS AND CONTRIBUTORS**

Keystone Symposia wishes to thank the following donors to the 2012 meeting series. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction among attending scientists.

**PARTNERS** ($10,000–$24,999)

Boehringer Ingelheim Stiftung
Cell Signaling Technology, Inc.
Gordon and Betty Moore Foundation
InterMune, Inc.*

JDRT
Landes Bioscience*
March of Dimes Foundation
Pfizer Oncology*

**PATRONS** ($5,000–$9,999)

Aastrom Biosciences, Inc.*
Alnylam Pharmaceuticals, Inc.*
Avanti Polar Lipids, Inc.
BioVentures, Inc.*
Coy Laboratory Products Inc.*
The Ellison Medical Foundation
Fältire Ireland
Genentech, Inc.*
ImQuest BioSciences*
Integrated DNA Technologies*
Janssen Research & Development LLC*

Mercodia, Inc.*
Educational grant from Millennium Pharmaceuticals, Inc., Novus Biologicals, Inc.*
Rigel Pharmaceuticals, Inc.*
Ruskin Technology Ltd, a division of the Baker Company, Inc.*
Seahorse Bioscience, Inc.
Sigma Life Science*
The Company of Biologists Ltd
Zymo Research Corporation*

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.
## Donor Support

**PARTNERS, PATRONS, DONORS AND CONTRIBUTORS (CONTINUED)**

### DONORS

($2,500–$4,999)

- ActivX Biosciences*
- Addgene*
- Adipogen International*
- Agilent Technologies*
- ALPCO Diagnostics*
- Alzheimer’s Drug Discovery Foundation
- Boston Biochem, an R&D Systems Company
- Bruker AXS, Inc.*
- Bruker BioSpin Corp.*
- CEDARLANE*
- ChemoCentryx, Inc.*
- Chroma Technology Corporation*
- Cubist Pharmaceuticals, Inc.*
- Cytokine journal
- Development, The Company of Biologists Ltd
- eBioscience, Inc.*
- Epizyme, Inc.
- Found Animals’ Michelson Prize & Grants in Reproductive Biology
- GenScript USA Inc.*
- Hain Lifescience GmbH
- HypOxygen*
- InQ Biosciences Corporation*
- iPierian, Inc.*
- ISOTEC, a member of the Sigma-Aldrich Group*
- Labome*
- Molecular and Cellular Proteomics
- Myriad-RBM*
- New England Biolabs, Inc.*
- Promedior, Inc.
- Promega Corporation
- R&D Systems, Inc.*
- Stromedix, Inc.*
- Syngenta Biotechnology, Inc.*
- Takeda California*
- Thermo Scientific

### CONTRIBUTORS

(up to $2,499)

- ACS Chemical Biology
- American Heart Association’s Council on Basic Cardiovascular Sciences
- Ampyx Pharmaceuticals, Inc.
- Avila Therapeutics
- Celera
- Department of Molecular Genetics and Microbiology, Duke University Medical Center
- GeneBlue Corporation*
- Journal of Biological Chemistry
- Journal of Lipid Research
- OneWorld Health
- Procter & Gamble Company
- Rigaku Americas Corporation*
- ViaCyte, Inc.

### US GOVERNMENT GRANTS

Keystone Symposia appreciates grants to support various 2012 meetings received from the following government agencies:

- National Institutes of Health (NIH):
  - National Cancer Institute (NCI)
  - National Human Genome Research Institute (NHGRI)
  - National Heart, Lung, and Blood Institute (NHLBI)
  - National Institute on Aging (NIA)
  - National Institute of Allergy and Infectious Diseases (NIAID)
  - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  - National Institute of Dental and Craniofacial Research (NIDCR)
  - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  - National Institute of Environmental Health Sciences (NIEHS)
  - National Institute of General Medical Sciences (NIGMS)
  - National Institute of Mental Health (NIMH)
  - National Institute of Neurological Disorders and Stroke (NINDS)
- National Science Foundation (NSF)

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

In March 1972, Keytone Symposia (then known as ICN-UCLA Symposium) held its first conference – on “Membrane Proteins” in Squaw Valley, California. Among the attendees was Emeritus Board Member Ed Dennis, pictured facing the camera to left of center.

Also in attendance at the inaugural Keystone Symposia meeting in 1972 was Nobel Laureate Arthur Kornberg, at left in the brown beret.

The conference in Squaw Valley laid the groundwork for future meetings in western ski resorts where participants could relax in an invigorating, natural setting while discussing hard science.
These generous alumni of previous meetings and others with a passion for ensuring a future of scientific discovery that benefits humankind have made gifts in the fiscal year ending June 30, 2012 to support the Keystone Symposia Future of Science Fund. Through their generosity, we are able to provide scholarships and travel awards to the next generation of biomedical and life scientists, whose education and careers are enhanced by the opportunity to attend meetings and interact with the world’s leading senior scientists.

In addition to funding for general and underrepresented minority scholarships and travel awards for investigators originating from countries most affected by topics of specific meetings, Future of Science Fund supporters can also contribute to help us meet general meeting program expenses, as well as program costs for specific meetings of their choice.

**Keystone Symposia Future of Science Fund Donors**

**PRESIDENT’S CIRCLE ($10,000+)**
The Elkes Foundation

**FOUNDERS’ SOCIETY ($5,000–$9,999)**
A.J. Miller
David and Marcy Woodland

**KEYSTONE CHAMPIONS ($1,000–$4,999)**
Jim and Sue Aiken
Christopher Atwood
Kenneth W. Bair
Margaret Liu, Robert Johnson
Anthony Pawson
Alessandro Pocai, Marco and Sofia Pocai with matching gift from Merck Partnership for Giving
Roy G. Michell Charitable Foundation and Trust
Sidney E. Frank Foundation
Craig B. Thompson
Jo Viney
Juleen Zierath

**KEYSTONE BENEFACTOR ($500–$999)**
Raymond N. DuBois
Joseph Heitman
Laura L. Kiessling, Ronald T. Raines
Michinori Kohara
Suraj Manrao Student Travel Fund
Terry J. Opgenorth
Andrew D. Robertson
Kazuo Tsubota
Sally Wenzel
Ian Wilson
Masayuki Yamamoto

**KEYSTONE PATRONS ($100–$499)**
Stephen Bartelmez, Elizabeth Bartelmez
Carole L. Bassett
Jeff Bergelson
Raymond Birge
Alberto Bosque
Vicki Boussiosi
Ralph A. Bradshaw
Sten Braesh-Andersen
Richard Breyer
Andrew Butler
Daniel H. Conway
Maria Valeria Corrias
Robert W. Craig
Shoulian Dong

**KEYSTONE PATRONS (continued)**
Robert H. Eckel
Lee Ellis
Beverly Emerson
John Foley
Sarah Gaffen
Curtis C. Harris
Michèle Himmelsbach
Takeshi Ikeuchi
Mark H. Kaplan
Christopher Karp
Kyung Hyun Kim
Young Ho Kim
Gerald Koelsch
Shohei Koide
Masayasu Kojima
Takeshi Kurose
Mahin D. Maines
Phyllis McNeil
Shi-Yuan (Tina) Meng with matching gift from Amgen Foundation Matching Gift Program
Jonathan Moore
Karim Nadra
Victor Nussenzwieg
Opokua Ofori-Aninyam
Eric Parker
Marc Prentki
Steven Reiner
Ole Petter Rekvig
Beverly Rothermel, in memory of Daphne Land Rothermel
Edward B. Sanders
Naoyuki Sato
Alan Sher
Yan Shi with matching gift from Bristol-Myers Squibb Company Employee Giving Program
Rebecca Shilling
Gregory T. Spear
Steven L. Reiner
Peter Strop
Gerald Sufrin
Lorraine Symington
Yutaka Tagaya
James W. Thomas
Tomoaki Horie
James B. Trager
Toshihiro Umehara
Terry Unterman
Jo Viney

**KEYSTONE PATRONS (continued)**
Sih-han Wang
Stephanie Wengert Watts
Marsha Wills Karp
Apriliano Eddy Wiria
Lawrence J Wysocki
Lawrence Wysocki
Shigei-yuki Yokoyama
Reza Zarnegar
Zongde Zhang
Anonymous (1)

**KEYSTONE CONTRIBUTORS ($10–$99)**
Mridu Acharya
Yasunori Aizawa
Stephen Anderson
Paulo Antas
Emily C. Barker
Ahmed Seif Baus
Linda Hildegarde Bergersen
Dalibor Blazek
Ramireddy Bommireddy
Steffen A. Borden
Laura Wells Bowers
Rolf A. Brekken
Violet Bumah
Byambajav Buyandelger
Erin Carlson
Kenneth E. Carlson
Romain Cartoni
Dhyana Chandra
Zhiyong Cheng
Elena Chertova
Auriee Cleret
Frank GJ Cobelens
Denise Cooper, in memory of Adam F. Cooper
Anne E. Corcoran
Carolyn B. Coyne
Roxanne Creveling
Bruce Cronstein
Pradhyot Dash
Geraint Rhys Davies
Xavier J. de Mollerat du Jeu
Guillaume Diss
Ugo D’Oro
Irina Dulubova
Iluis Espinosa
Unseasonably warm weather in the Rockies made this a popular sight at 2012 conferences, including the joint meetings on “Innate Immunity” and “The Microbiome” at Keystone Resort, Colorado in March 2012.

Dr. Richard A. Young of Whitehead Institute of Biomedical Research delivered the joint keynote address at the meetings on “Epigenomics” and “Chromatin Dynamics” at Keystone Resort in January 2012.

In May 2012, we held our second meeting in Kampala, Uganda – on “Drug Resistance and Persistence in Tuberculosis.”

In conjunction with the first meeting on Traumatic Brain Injury, Keystone Symposia hosted a free community forum attended by approximately 150 people at the Pavilion in Silverthorne, Colorado.
Keystone Symposia In-Kind Donors

MARKETING/ADVERTISING IN-KIND DONORS

The following publishers, societies and other organizations provided in-kind marketing and advertising support that helped publicize the 2012 Keystone Symposia meeting series.

BENEFACTORS ($50,000+)
BioMed Central Ltd
Cell Press
Nature Publishing Group
The Scientist
Wiley-Blackwell

SPONSORS ($25,000–$49,999)
American Association for the Advancement of Science
Cold Spring Harbor Laboratory Press
Landes Bioscience
The Rockefeller University Press – The Journal of Cell Biology

PARTNERS ($10,000–$24,999)
ACS Chemical Biology
ACS Publications
EMBO (European Molecular Biology Organization)
FOCIS (Federation of Clinical Immunology Societies)
Mary Ann Liebert, Inc. publishers
PLOS
Proceedings of the National Academy of Sciences (PNAS)
Pubget Inc.
The Rockefeller University Press – The Journal of Experimental Medicine

PATRONS ($5,000–$9,999)
Royal Society of Chemistry
S. Karger A.G.
The Company of Biologists Ltd
The Journal of Rheumatology

CONTRIBUTORS (up to $2,499)
Beatson Institute for Cancer Research
Co-Action Publishing
EMBL (European Molecular Biology Laboratory)
SAGE Publications
The Journal of Clinical Investigation

SPEAKER GIFT-IN-KIND DONORS

The following companies generously agreed to forego reimbursements for speaker travel and lodging expenses in order to support 2012 Keystone Symposia meeting programs.

Amgen Inc.
Anacor Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
AstraZeneca
Athersys Inc.
Avid Radiopharmaceuticals, Inc.
Avila Therapeutics
Bristol-Myers Squibb Company
Carmot Therapeutics, Inc.
Crucell
Dynavax Technologies Corporation
Eli Lilly and Company
EMBO Young Investigator Programme
Epizyme, Inc.
Genentech, Inc.
Genomics Institute of the Novartis Research Foundation
Genzyme Corporation
GlaxoSmithKline
GlaxoSmithKline / DDDW
GlaxoSmithKline R&D China
Heptares Therapeutics Ltd
Hoffmann-La Roche, Inc.
Isis Pharmaceuticals, Inc.
MedImmune
Merck & Co., Inc.
Merck Research Laboratories
Metabolic Solutions Development Company, LLC.
Millennium Pharmaceuticals, Inc., The Takeda Oncology Company
Novartis Institute for Tropical Diseases
Novartis Institutes for BioMedical Research
Novartis Pharma AG
Optibrium Ltd.
Osiris Therapeutics, Inc.
Pacific Biosciences
Prosensa Therapeutics
Regeneron Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
RXi Pharmaceuticals
Scynexis, Inc.
Sirtris, a GSK Company
Stromedix, Inc.
Tekmira
Tibotec BVBA
ViaCyte, Inc.
Board of Directors (as of June 30, 2012)

Juleen R. Zierath, Ph.D.
Chair of the Board, Keystone Symposia
Professor, Molecular Medicine and Surgery, Karolinska Institutet

Craig B. Thompson, M.D.
Secretary of the Board
Chair, Scientific Advisory Board, Keystone Symposia
President and CEO, Memorial Sloan-Kettering Cancer Center

Terry J. Opgenorth, Ph.D.
Treasurer of the Board
Chair, Finance Committee, Keystone Symposia
Chief Operating Officer, NeoTREX
CSU Ventures, Inc., Colorado State University

James W. Aiken, Ph.D.
President and Chief Executive Officer
Keystone Symposia on Molecular and Cellular Biology

Kenneth W. Bair, Ph.D.
Chair, Audit Committee, Keystone Symposia
Senior Vice President and Head, Research and Development
Forma Therapeutics, Inc.

Beverly M. Emerson, Ph.D.
Chair, Personnel Committee, Keystone Symposia
Professor, Regulatory Biology Laboratory
The Salk Institute

Peter M. Finan, Ph.D.
Director, Pathways Biology
Developmental and Molecular Pathways
Novartis Institutes for BioMedical Research

Heidi E. Hamm, Ph.D.
Professor and Chair, Department of Pharmacology
Vanderbilt University School of Medicine

Edison T. Liu, M.D.
President and Chief Executive Officer
The Jackson Laboratory

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.
Professor Emeritus, Physiology and Biophysics
College of Medicine, University of California, Irvine

Edward A. Dennis, Ph.D.
Professor, Chemistry, Biochemistry and Pharmacology
School of Medicine, University of California, San Diego

Curtis C. Harris, M.D.
Chief, Laboratory of Human Carcinogenesis
NCI/National Institutes of Health

Staff (as of June 30, 2012)

James Aiken, Chief Executive Officer
Pamela Daugherty, Chief Financial Officer
David Woodland, Chief Scientific Officer
Jeannie Dalrymple, Senior Director, Program Development
& Implementation
Linda Hrycaj, Senior Director, Strategic Planning
Christopher Atwood, Director, Development
Heidi Daetwyler-Simpson, Director, Meeting Management
Laina King, Director, Diversity in Life Science Programs
Tanya Muller, Director, Information Technology
Yvonne Psaila, Director, Marketing & Communications
Mary Jo Roal, Director, Human Resources

David Adamson, On-Site Representative
Cathy Banks, Web Developer/Systems Analyst
Kellan Barr, Marketing & Publications Coordinator
Carol Bosserman, On-Site Representative
Mary Brown, On-Site Representative
Caroline Brendel, Executive Administrative Assistant
Melissa Carrera, Assistant Director of Development
Linda Cooper, Publications Assistant
Doug Castle, Information Technology Programmer

Margaret A. Liu, M.D.
Chair, Development Committee, Keystone Symposia
ProTherImmune; Visiting Professor, Karolinska Institutet

Gary J. Nabel, M.D., Ph.D.
Bethesda, Maryland

Tony Pawson, Ph.D.
Senior Investigator
Centre for Systems Biology, Samuel Lunenfeld Research Institute

Alan Sher, Ph.D.
Chair, Nominating Committee, Keystone Symposia
Bethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRS
Professor, Department of Molecular Biology
and The Skaggs Institute for Chemical Biology
The Scripps Research Institute

David L. Woodland, Ph.D.
Chief Scientific Officer
Keystone Symposia on Molecular and Cellular Biology

Amanda Deem, Assistant Director of Development
Heather Gerhart, Senior Grants Coordinator/Program Analyst
Susan Gunn, Seasonal Logistics Assistant
Lindsey Heilmann, Conference Coordinator
Jenny Hindorff, Program Implementation Associate
Sarah Lavicka, Administrative & Research Assistant, Development
Jeff Lehman, Scholarship Coordinator
Phyllis McNeil, Attendee Services Representative
Allison Ogdon, Program Development Coordinator
Annie Page, On-Site Representative
McKennzie Rains, IT Support/Assistant
Grace Roath, Office Manager
Julie Roll, On-Site Representative
David Sanchez, Manager, Attendee Services
Barbara Schmid-Miller, Program Implementation Assistant
Gwyn Schmude, Attendee Services Representative
Dawn Shafer, Accounting Clerk
Bridget Stacy, Administrative Assistant, Diversity
Kathy Tavares, Program Development/Implementation Supervisor
Rebecca Wilkerson, Finance Assistant

Mary Brown
On-Site Representative